Logo

Orig3n

FDA Grants EUAs to Coronavirus Tests From Orig3n, SDI, UNC

The FDA has also granted emergency use authorization for PCR-based tests for SARS-CoV-2 developed by Orig3n, Specialty Diagnostic Laboratories (SDI), and the University of North Carolina (UNC) Medical Center.

Orig3n's Purchase of Interleukin's CLIA Lab May Appease CMS, But Some Question Plans for Test Assets
Premium

A number of experts have questioned the clinical validity underlying Interleukin's tests and hope Orig3n will not revive them.

Orig3n Acquires Interleukin Genetics CLIA Lab, Remaining Assets

Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.

Dental Association Advances Resolution on Genetic Test Validity

The American Dental Association wants insurers and test manufacturers to show genetic testing is scientifically valid before they're used to determine coverage eligibility.

Interleukin Genetics to Liquidate Assets

The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test.

Jul 11, 2017

Controversial Gum Disease Risk Test Highlights Precision Medicine Marketing, Regulatory Issues

Jul 4, 2017

Interleukin Shutting Down Genetic Testing Program, Lays Off Staff

May 12, 2017

In Brief This Week: Alere, Fulgent Diagnostics, Trovagene, Great Basin, and More

Aug 1, 2016

Interleukin Genetics to Sell $5.6M in Stock, Warrants

May 16, 2016

Interleukin Posts Increased Q1 Revenues

Mar 17, 2016

Interleukin Genetics Q4 Revenues Up 14 Percent

Nov 13, 2015

Interleukin Genetics Q3 Revenues Down 59 Percent on Fewer Processed Test Kits

Nov 10, 2015

FDA Sends Interleukin Genetics, DNA-CardioCheck Untitled Letters

Aug 14, 2015

Interleukin Genetics' Q2 Revenues Decline 29 Percent

Jul 15, 2015

Interleukin, NYU to Commercialize IL-1 Genetic Test for Osteoarthritis Progression

May 15, 2015

Interleukin Genetics Q1 Revenues Drop 17 Percent

Mar 24, 2015

Divergent Findings on Interleukin Gum Disease Risk Test Raise Questions about Clinical Use
Premium

Mar 20, 2015

Interleukin Posts Q4 Revenue Drop as It Continues Commercial Push for PerioPredict

Mar 9, 2015

Interleukin Genetics, Isis Pharma Expand Drug Testing Collaboration

Jan 7, 2015

Interleukin Genetics to Provide Testing Services to Isis for Clinical Study

Dec 24, 2014

Interleukin Genetics Secures $10M in Financing

Apr 22, 2014

New York Conditionally Approves Interleukin to Provide Genetic Test for Periodontal Disease

Mar 21, 2014

Interleukin Genetics Nearly Doubles Revenues in Q4

Jun 12, 2013

Interleukin Publishes Large Study Involving PST Test to Stratify Patients at Risk of Gum Disease
Premium

May 20, 2013

Interleukin Genetics Raises $12M in Private Placement

Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.